234 related articles for article (PubMed ID: 9717867)
1. Cognitive and behavioral therapies alone versus in combination with fluvoxamine in the treatment of obsessive compulsive disorder.
van Balkom AJ; de Haan E; van Oppen P; Spinhoven P; Hoogduin KA; van Dyck R
J Nerv Ment Dis; 1998 Aug; 186(8):492-9. PubMed ID: 9717867
[TBL] [Abstract][Full Text] [Related]
2. Cognitive therapy and exposure in vivo alone and in combination with fluvoxamine in obsessive-compulsive disorder: a 5-year follow-up.
van Oppen P; van Balkom AJ; de Haan E; van Dyck R
J Clin Psychiatry; 2005 Nov; 66(11):1415-22. PubMed ID: 16420079
[TBL] [Abstract][Full Text] [Related]
3. The effect of fluvoxamine and behavior therapy on children and adolescents with obsessive-compulsive disorder.
Neziroglu F; Yaryura-Tobias JA; Walz J; McKay D
J Child Adolesc Psychopharmacol; 2000; 10(4):295-306. PubMed ID: 11191690
[TBL] [Abstract][Full Text] [Related]
4. Cognitive therapy and exposure in vivo in the treatment of obsessive compulsive disorder.
van Oppen P; de Haan E; van Balkom AJ; Spinhoven P; Hoogduin K; van Dyck R
Behav Res Ther; 1995 May; 33(4):379-90. PubMed ID: 7755525
[TBL] [Abstract][Full Text] [Related]
5. Haloperidol addition in fluvoxamine-refractory obsessive-compulsive disorder. A double-blind, placebo-controlled study in patients with and without tics.
McDougle CJ; Goodman WK; Leckman JF; Lee NC; Heninger GR; Price LH
Arch Gen Psychiatry; 1994 Apr; 51(4):302-8. PubMed ID: 8161290
[TBL] [Abstract][Full Text] [Related]
6. Long-term course and outcome of obsessive-compulsive patients after cognitive-behavioral therapy in combination with either fluvoxamine or placebo: a 7-year follow-up of a randomized double-blind trial.
Rufer M; Hand I; Alsleben H; Braatz A; Ortmann J; Katenkamp B; Fricke S; Peter H
Eur Arch Psychiatry Clin Neurosci; 2005 Apr; 255(2):121-8. PubMed ID: 15812606
[TBL] [Abstract][Full Text] [Related]
7. Cognitive-behavioral therapy as an adjunct to serotonin reuptake inhibitors in obsessive-compulsive disorder: an open trial.
Simpson HB; Gorfinkle KS; Liebowitz MR
J Clin Psychiatry; 1999 Sep; 60(9):584-90. PubMed ID: 10520976
[TBL] [Abstract][Full Text] [Related]
8. Low-dose risperidone augmentation of fluvoxamine treatment in obsessive-compulsive disorder: a double-blind, placebo-controlled study.
Erzegovesi S; Guglielmo E; Siliprandi F; Bellodi L
Eur Neuropsychopharmacol; 2005 Jan; 15(1):69-74. PubMed ID: 15572275
[TBL] [Abstract][Full Text] [Related]
9. Predictive value of obsessive-compulsive personality disorder in antiobsessional pharmacological treatment.
Cavedini P; Erzegovesi S; Ronchi P; Bellodi L
Eur Neuropsychopharmacol; 1997 Feb; 7(1):45-9. PubMed ID: 9088884
[TBL] [Abstract][Full Text] [Related]
10. No talking, just writing! Efficacy of an Internet-based cognitive behavioral therapy with exposure and response prevention in obsessive compulsive disorder.
Herbst N; Voderholzer U; Thiel N; Schaub R; Knaevelsrud C; Stracke S; Hertenstein E; Nissen C; Külz AK
Psychother Psychosom; 2014; 83(3):165-75. PubMed ID: 24732962
[TBL] [Abstract][Full Text] [Related]
11. Fluvoxamine versus clomipramine in the treatment of obsessive compulsive disorder: a multicenter, randomized, double-blind, parallel group comparison.
Freeman CP; Trimble MR; Deakin JF; Stokes TM; Ashford JJ
J Clin Psychiatry; 1994 Jul; 55(7):301-5. PubMed ID: 8071291
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of fluvoxamine, paroxetine, and citalopram in the treatment of obsessive-compulsive disorder: a single-blind study.
Mundo E; Bianchi L; Bellodi L
J Clin Psychopharmacol; 1997 Aug; 17(4):267-71. PubMed ID: 9241005
[TBL] [Abstract][Full Text] [Related]
13. Parental obsessive-compulsive disorder as a prognostic factor in a year long fluvoxamine treatment in childhood and adolescent obsessive-compulsive disorder.
Yaryura-Tobias JA; Grunes MS; Walz J; Neziroglu F
Int Clin Psychopharmacol; 2000 May; 15(3):163-8. PubMed ID: 10870874
[TBL] [Abstract][Full Text] [Related]
14. The efficacy of fluvoxamine in obsessive-compulsive disorder: effects of comorbid chronic tic disorder.
McDougle CJ; Goodman WK; Leckman JF; Barr LC; Heninger GR; Price LH
J Clin Psychopharmacol; 1993 Oct; 13(5):354-8. PubMed ID: 8227493
[TBL] [Abstract][Full Text] [Related]
15. An open study of fluvoxamine augmentation of neuroleptics in schizophrenia with obsessive and compulsive symptoms.
Reznik I; Sirota P
Clin Neuropharmacol; 2000; 23(3):157-60. PubMed ID: 10895399
[TBL] [Abstract][Full Text] [Related]
16. Memantine add-on in moderate to severe obsessive-compulsive disorder: randomized double-blind placebo-controlled study.
Ghaleiha A; Entezari N; Modabbernia A; Najand B; Askari N; Tabrizi M; Ashrafi M; Hajiaghaee R; Akhondzadeh S
J Psychiatr Res; 2013 Feb; 47(2):175-80. PubMed ID: 23063327
[TBL] [Abstract][Full Text] [Related]
17. Efficacy of cognitive behavioural therapy with medication for patients with obsessive-compulsive disorder: A multicentre randomised controlled trial in China.
Meng FQ; Han HY; Luo J; Liu J; Liu ZR; Tang Y; Hou X; Wei J; Shi LL; Tang MN; Yan YP; Huang YQ; Sun J; Li ZJ
J Affect Disord; 2019 Jun; 253():184-192. PubMed ID: 31108379
[TBL] [Abstract][Full Text] [Related]
18. Exposure therapy, fluvoxamine, or combination treatment in obsessive-compulsive disorder: one-year followup.
Cottraux J; Mollard E; Bouvard M; Marks I
Psychiatry Res; 1993 Oct; 49(1):63-75. PubMed ID: 8140182
[TBL] [Abstract][Full Text] [Related]
19. L-carnosine as an adjuvant to fluvoxamine in treatment of obsessive compulsive disorder: A randomized double-blind study.
Arabzadeh S; Shahhossenie M; Mesgarpour B; Rezaei F; Shalbafan MR; Ghiasi Z; Akhondzadeh S
Hum Psychopharmacol; 2017 Jul; 32(4):. PubMed ID: 28485008
[TBL] [Abstract][Full Text] [Related]
20. Comparing the Effects of a Herbal Drug based on
Noras MR; Soltanifar A; Salari R; Jarahi L; Abrishami MH
Curr Drug Discov Technol; 2022; 19(5):e240622206368. PubMed ID: 35748547
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
